Mexidol after moderate ischemic stroke: MIR placebo-controlled trial
Randomized study in people · 2025
- What was studied
- 304 randomized, 152 per arm. Primary per-protocol analysis: 141 Mexidol and 138 placebo.
- Main finding
- By about day 71, disability scores changed by −2.45 points with Mexidol and −2.01 with placebo (p=0.00313). At follow-up, 60% vs 41% scored 0–1 on the modified Rankin Scale. The paper reported adverse events in 35 of 152 participants in each arm.
Reported findings and study design
International double-blind randomized parallel-group comparison in first-ever moderate ischemic stroke. 152 participants per group. Primary per-protocol analysis included 141 Mexidol and 138 placebo recipients.
Population or model 304 randomized, 152 per arm. Primary per-protocol analysis: 141 Mexidol and 138 placebo.
Dose, route and schedule
Standard care plus 500 mg Mexidol intravenously twice daily for 10 days, followed by 250 mg orally three times daily for 60 days. Controls received standard care and matching IV and oral placebo.
Protocol source ↗ · Published full-text trial tables and ClinicalTrials.gov results (NCT06437626).
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Change in disability score (mRS) | −2.45 vs −2.01 points | Mexidol vs placebo, 141 vs 138 analyzed · Day 71 · p=0.00313 |
| mRS score 0–1 | 60% vs 41% | Mexidol vs placebo, per protocol · Day 71 · p=0.002 |
| Participants with an adverse event | 35/152 (23%) in each arm | Journal counts: 42 events vs 43 · p=1.000 |
MIR disability outcomes by analysis population
| Outcome | Per protocol: Mexidol vs placebo | Intention to treat: Mexidol vs placebo |
|---|---|---|
| mRS change at end of oral phase | −2.45 vs −2.01 (p=0.00313) | −2.32 vs −1.90 (p=0.00384) |
| mRS 0–1 at end of oral phase | 60% vs 41% (p=0.002) | 57% vs 39% (p=0.002) |
| mRS ≥3 at end of oral phase | 16% vs 28% (p=0.016) | 20% vs 32% (p=0.019) |
| Median mRS change after IV phase | −1 vs −1 (p=0.8) | −1 vs −1 (p=0.8) |
Table 3. Lower mRS scores indicate less disability. The registry reports arm-level 95% confidence intervals for primary change of −2.70 to −2.23 and −2.25 to −1.87. The article’s prose and table differ in how they label the primary estimate.
The primary endpoint favored Mexidol over placebo at the end of the 70-day treatment course. The registry lists serious adverse events in six vs four participants and deaths in two vs one. The trial gives limited information on rare harms and on people receiving reperfusion.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The trial enrolled patients with first-ever moderate ischemic stroke who did not receive reperfusion. Generalizability to thrombolysis or thrombectomy is uncertain.
- The primary analysis was per protocol. The intention-to-treat result also favored Mexidol. The US registry first posted the study after completion.
- The journal reports 35 participants with events in each arm. The registry lists 36 vs 39 participants in its nonserious-events category. The reports do not reconcile those totals.
Related publications may describe some of the same participants or experiments.
Source details
Published full-text trial tables and ClinicalTrials.gov results (NCT06437626).
Sources checked
Citation
N. A. Shamalov, A. I. Fedin, G. S. Rakhimbaeva, et al.. Mexidol after moderate ischemic stroke: MIR placebo-controlled trial Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(8 Suppl 2):40–53. NCT06437626.
Study source ↗ · DOI 10.17116/jnevro202512508240 · Bibliography entry · Link to this summary